2025– date –
-
molmir has been selected as a startup for the Nakanoshima Qross Drug Discovery and Practical Application Promotion Program Support Project
molmir, Inc. has been selected as a startup for the Nakanoshima Qross Drug Discovery and Practical Application Promotion Program Support Project, which was adopted by the Ministry of Health, Labor and Welfare's Drug Discovery Cluster Cam... -
molmir and OrganoTherapeutics announce strategic R&D collaboration~ accelerate developing therapeutics for Parkinson’s disease with 3D midbrain organoids~
molmir Inc. (based in Nara, Japan, CEO: Eiichiro Mori, M.D., Ph.D.) is proud to announce that it has entered into an agreement with OrganoTherapeutics SARL (based in Esch-sur-Alzette, Luxembourg, CEO: Jens Schwamborn, Ph.D.) for R&D ... -
molmir was awarded the MU-TECH Research and Development Grant
Mitsubishi UFJ Technology Development Foundation, MU-TECH, has nominated molmir as an entity to be subsized by the FY 2024 second research development grant. The judging committee selected 5 projects capable of delivering solution or nov... -
molmir commenced on business development toward British life science ecosystem during the JETRO supported BioUK Launchpad
molmir was nominated to participate in the J-StarX program which delegates entrepreneurs to overseas community, initiated by JETRO, Japan External Trade Organization and METI, Ministry of Economy, Trade and Industry of Japan. BioUK is an... -
molmir was awarded at Deep Tech Venture of the Year 2025
molmir was honored at the "Deep Tech Venture of the Year 2025" award program in Startup category, hosted by Leave a Nest Co., Ltd. on January 29, 2025. The ceremony recognized deep tech startups that were taking on the challenge of solvi...
1